Caxton Associates LP Lyell Immunopharma, Inc. Transaction History

Caxton Associates LP

  • $2.65 Billion
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024
BUY
$1.71 - $3.07 $233,604 - $419,395
136,611 Added 359.07%
174,657 $389,000
Q4 2023

Feb 14, 2024
SELL
$1.39 - $2.35 $222,999 - $377,012
-160,431 Reduced 80.83%
38,046 $73,000
Q3 2023

Nov 14, 2023
BUY
$1.45 - $3.35 $223,392 - $516,114
154,064 Added 346.89%
198,477 $291,000
Q2 2023

Aug 14, 2023
BUY
$1.89 - $3.86 $83,940 - $171,434
44,413 New
44,413 $141,000

Others Institutions Holding LYEL

# of Institutions
121
Shares Held
142M
Call Options Held
18.1K
Put Options Held
200
View Full List

About Lyell Immunopharma, Inc.

LYEL Quotes by TradingView
  • Ticker LYEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 247,824,992
  • Market Cap $151M
  • Description
  • Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate...
More about LYEL
Track This Portfolio

Track Caxton Associates LP Portfolio

Follow Caxton Associates LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Caxton Associates LP, based on Form 13F filings with the SEC.

News

Stay updated on Caxton Associates LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email